News Search Results
Oct 18, 2025, 06:00 ET Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Oct 17, 2025, 08:30 ET Cohen & Steers Infrastructure Fund, Inc. Announces Preliminary Results of Transferable Rights Offering
https://www.cohenandsteers.com/Symbols: (NYSE: CNS, UTF)
More news about: Cohen & Steers, Inc.
Oct 16, 2025, 20:00 ET XLC Memilih Corero Network Security Untuk Tingkatkan Pertahanan DDoS di Seluruh Lokasi Baru di Asia Pasifik
Corero Network Security (AIM: CNS) (OTCQX: DDOSF) adalah perusahaan terdepan yang diakui di bidang perlindungan DDoS dan yang terbaik dalam hal ketersediaan layanan adaptif di waktu nyata.
More news about: Corero Network Security
Oct 16, 2025, 16:27 ET COHEN & STEERS REPORTS RESULTS FOR THIRD QUARTER 2025
NEW YORK, Oct. 16, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended September 30, 2025. The earnings release along with the accompanying earnings presentation can be viewed
More news about: Cohen & Steers, Inc.
Oct 16, 2025, 13:59 ET Vivistim Co-Founder Named Innovator of the Year by the Congress of Neurological Surgeons
"We're proud of Navzer for being named CNS' Innovator of the Year," said Richard Foust, CEO of MicroTransponder. "His pioneering work on Paired VNS Therapy continues to help stroke survivors reclaim meaningful lives. The growing real-world evidence presented at the CNS Annual Meeting and the enthusiastic
More news about: MicroTransponder Inc.
Oct 16, 2025, 09:00 ET Connecticut Innovations' AI/Q Fund Invests in Two Frontier AI Opportunities: Yuma Asset Management and Bexorg
neurodegenerative diseases such as Alzheimer's and Parkinson's, with potential to expand into a broad range of CNS diseases. Over time, Bexorg aims to accelerate strategic partnerships and internal CNS development programs with its integrated AI and precision neurology platform. "These
More news about: Connecticut Innovations
Oct 16, 2025, 08:45 ET Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis
3:12.MS is characterized by focal lymphocytic CNS infiltration leading to myelin destruction and axonal damage, which result in neurologic syndromes and physical disability3. MS clinical manifestations depend on the location of lesions in the CNS. Symptoms may include sensory and visual disturbances;
More news about: IASO Bio
Oct 16, 2025, 08:30 ET Deconstructing OCD Through the Use of Multiple Operant Behavioral Tasks in Rodents, Upcoming Webinar Hosted by Xtalks
TORONTO, Oct. 16, 2025 /PRNewswire/ -- Despite decades of research, the development of central nervous system (CNS) drugs continues to face significant challenges. The majority of compounds targeting psychiatric indications fail in clinical trials, including an unmet
More news about: Xtalks
Oct 16, 2025, 08:05 ET Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Oct 15, 2025, 16:30 ET Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
neurological conditions. Viatris received rights to develop and commercialize pitolisant and Spydia®, two assets in the Central Nervous System (CNS) therapy area, further expanding Viatris' portfolio of innovative products in Japan. As part of the transaction, Viatris has acquired
More news about: Viatris Inc.
Oct 15, 2025, 11:54 ET Electronic Grade SiH₄ Silane Gas Market to Reach $5.36B by 2031, Driven by Semiconductors & Solar | Valuates Reports
derivatives for solar and semiconductor use. Taiyo Nippon Sanso, Mitsui Chemicals, SIAD, Inner Mongolia Xingyang Technology, CNS, and ACE Gases. The top five companies control approximately 47% of the global market. Their strategies
More news about: Valuates Reports
Oct 15, 2025, 10:00 ET Metastatic Brain Tumor Collaborative Announces First-Ever Collaborative Grant Opportunity Focused on CNS Metastasis
innovative projects aimed at improving the diagnosis, treatment, and understanding of central nervous system (CNS) metastases. This represents the first-ever collaborative grant opportunity dedicated to CNS metastasis, made possible through the collective effort of ten leading nonprofit cancer organizations.
More news about: American Brain Tumor Association
Oct 15, 2025, 08:00 ET Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood
More news about: Indivior PLC
Oct 15, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
Conference Panel "Battleground States for Muscular Dystrophies": Tuesday, October 21 at 2:00 p.m. ET Panel "CNS GT – Lessons from Mature Programs & the Field's Next Frontiers": Tuesday, October 21 at 2:45 p.m. ET Location: New York, NY
More news about: REGENXBIO Inc.
Oct 15, 2025, 03:30 ET Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson's disease candidate MTX325 through clinical trials
in Parkinson's disease. Phase 1a SAD/MAD was successfully completed in healthy volunteers and CSF sampling confirmed a high level of penetration into CNS. PET study further confirmed distribution into brain parenchyma. Proof-of-mechanism biomarker and imaging data in PD patients
More news about: Mission Therapeutics
Oct 14, 2025, 17:31 ET Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics,
More news about: DelveInsight Business Research, LLP
Oct 14, 2025, 09:00 ET iQure Pharma Enters into Research Collaboration with the University of Padova
2025 /PRNewswire/ -- iQure Pharma, a clinical-stage biotech company breaking the cycle of excitotoxicity by restoring glutamate balance to treat CNS disorders, today announced it has entered into a research collaboration with Associate Professor Laura Civiero from the University of Padova.
More news about: iQure Pharma Inc.
Oct 13, 2025, 04:00 ET Cumulus Neuroscience Presents Data at the International Society for CNS Clinical Trials and Methodology Autumn Conference and the 38th European College of Neuropsychopharmacology Congress
Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference and the 38th European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam, the Netherlands. Traditional clinical trials for disorders and diseases of the central nervous system (CNS) like
More news about: Cumulus Neuroscience
Oct 12, 2025, 20:00 ET Verkada, 김기훈 신임 한국 지사장 선임
것"이라고 포부를 밝혔다. 김 지사장의 임명은 버카다가 아시아태평양 지역에서 사업 확장을 이어가는 가운데 이루어졌다. 버카다는 지난 1년간 이 지역에서 고객 기반을 60% 이상 성장시켰으며, SK쉴더스(SK Shieldus), LG CNS, LS사우타(LS Sauter) 등 주요 현지 기업과의 전략적 파트너십을 통해 성장세를 강화하고 있다. 버카다 소개 |
More news about: Verkada
Oct 12, 2025, 18:27 ET Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
decrease in CNS lesions was observed. These preliminary results suggest the potential for zipalertinib to treat these patients, warranting future investigation." Authors will report results from the REZILIENT2 study of zipalertinib against active CNS metastases
More news about: Taiho Oncology
Oct 10, 2025, 15:31 ET Alamar Biosciences Luncurkan NULISAqpcr™ BD-pTau217 Assay: Terobosan Deteksi Biomarker Non Invasif Khusus Otak Untuk Penelitian Penyakit Alzheimer
menjadi kandidat uji klinis terapi modifikasi penyakit." Tersedia sebagai NULISAqpcr assay single-plex atau dalam NULISAseq™ CNS Disease Panel 120 multipleks, BD-pTau217 assay akan mendukung penelitian penemuan maupun penelitian translasi. Alur kerja otomatis pada uji ini memungkinkan
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 14:33 ET Alamar Biosciences запускает анализ NULISAqpcr™ BD-pTau217 -- Прорывное достижение в неинвазивных методах обнаружения специфических биомаркеров мозга для исследований болезни Альцгеймера
лечения, модифицирующих заболевание». Доступный в виде однокомпонентного анализа NULISAqpcr или в мультиплексной панели NULISAseq™ CNS Disease Panel 120, анализ BD-pTau217 будет поддерживать как открытия, так и трансляционные исследования. Автоматизированная рабочая процедура анализа
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 14:11 ET Společnost Alamar Biosciences uvádí na trh test NULISAqpcr™ BD-pTau217: průlom v neinvazivní detekci biomarkerů specifických pro mozek v rámci výzkumu Alzheimerovy choroby
tauopatií. Tento první test svého druhu je jediným dostupným singleplexovým řešením odvozeným z mozku a stanovuje nový standard pro přesnost a specifičnost CNS (centrálního nervového systému) ve výzkumu neurodegenerativních onemocnění.
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 14:06 ET Alamar Biosciences uvádza na trh test NULISAqpcr™ BD-pTau217: Prevratnú novinku v neinvazívnej detekcii biomarkerov špecifických pre mozog na výskum Alzheimerovej choroby
prvý test svojho druhu je jediným dostupným jednoplexným riešením odvodeným od mozgu, ktorý stanovuje nové kritérium pre presnosť a špecificitu pre CNS vo výskume neurodegeneratívnych ochorení.
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 14:03 ET Alamar Biosciences wprowadza test NULISAqpcr™ BD-pTau217: Przełom w dziedzinie nieinwazyjnego wykrywania swoistych dla mózgu biomarkerów stosowanych w badaniach choroby Alzheimera
choroby". Dostępne w formie jednoparametrowego testu NULISAqpcr lub w ramach panelu chorób ośrodkowego układu nerwowego NULISAseq™ CNS Disease Panel 120, rozwiązanie BD-pTau217 sprawdzi się zarówno w badaniach ukierunkowanych na nowe odkrycia jak i w badaniach translacyjnych. Zautomatyzowany
More news about: Alamar Biosciences, Inc.